false
Catalog
2024 Asia Conference on Lung Cancer (ACLC) - Poste ...
PP02.13 - Hiroki Imabayashi
PP02.13 - Hiroki Imabayashi
Back to course
Pdf Summary
This study investigates the clinical features and outcomes of invasive mucinous adenocarcinoma (IMA) and mixed invasive mucinous and non-mucinous adenocarcinoma (mixed IMA) in lung cancer cases operated on at Chiba University Hospital from January 2012 to December 2023. The research involved a retrospective chart review of 82 IMA cases and 8 mixed IMA cases.<br /><br />IMA is an uncommon form of adenocarcinoma, while mixed IMA is even rarer and less often documented. The study used comparative analyses involving the χ2 test, Mann-Whitney U test, and log-rank test to evaluate differences between the groups.<br /><br />Key findings indicate that mixed IMA is associated with a poorer Relapse Free Survival (RFS) rate compared to IMA. Specifically, mixed IMA shows a higher recurrence rate, notably when the pathological tumor size (pTsize) exceeds 4.4 cm. The study emphasizes the need for comprehensive evaluation in cases with larger tumors not confined to the lower lobe for better prognostication.<br /><br />Statistically significant differences found between the groups include the percentage of tumors located in the lower lobe (80.5% in IMA vs. 37.5% in mixed IMA, p=0.006) and a higher recurrence rate in mixed IMA (50% vs. 19.5% in IMA, p=0.048). Although tumors in mixed IMA are generally larger (median pTsize 5.4 cm vs. 2.4 cm in IMA, p=0.07), this was not statistically significant.<br /><br />Overall, mixed IMA patients have worse Progression Free Survival (PFS) than those with pure IMA. The study suggests that non-mucinous morphology within mixed IMA could indicate tumor progression, demanding careful monitoring and management. The authors disclosed no financial conflicts of interest.
Keywords
invasive mucinous adenocarcinoma
mixed IMA
lung cancer
Chiba University Hospital
retrospective chart review
Relapse Free Survival
pathological tumor size
lower lobe tumors
Progression Free Survival
tumor recurrence
×
Please select your language
1
English